Insider Trading November 19, 2026 03:45 AM

RA Capital Adds to SpyGlass Pharma Stake with $32,430 Purchase

The 10% owner and director bought 1,000 shares at an average price of $32.43, even as the stock has pulled back 11% over the past week.

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
SGP

RA Capital Management, L.P., a director and 10% owner of SpyGlass Pharma, Inc. (NASDAQ:SGP), acquired 1,000 shares of common stock on November 16, 2026, at a weighted average price of $32.43 per share, for a total of $32,430. The purchase occurred as SpyGlass shares have declined 11% over the past week to $29.68, though they remain up 40% over the past six months. RA Capital indirectly holds 5,967,439 shares through RA Capital Healthcare Fund, L.P., and 2,054,678 shares through RA Capital Nexus III Fund, L.P. Dr. Zachary Scheiner, a principal of RA Capital, serves on SpyGlass's board. In other developments, SpyGlass reported positive four-year trial results for its Bimatoprost Drug Pad-IOL System, showing a 37% reduction in intraocular pressure, leading H.C. Wainwright to reiterate a Buy rating and $37 price target. The company also acquired Advanced Vision Science for approximately $13 million in cash, prompting Stifel to maintain a Buy rating and adjust its price target to $44.00. Analysts maintain a strong buy consensus with price targets ranging from $42 to $62, though the stock appears overvalued relative to Fair Value according to InvestingPro analysis.

RA Capital Adds to SpyGlass Pharma Stake with $32,430 Purchase
SGP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • RA Capital Management, a 10% owner and director of SpyGlass Pharma, purchased 1,000 shares at an average price of $32.43, totaling $32,430, signaling continued insider confidence despite recent stock weakness.
  • SpyGlass shares have fallen 11% over the past week to $29.68 but remain up 40% over six months, reflecting volatility in the medical device sector.
  • Positive four-year trial data for the Bimatoprost Drug Pad-IOL System and the acquisition of Advanced Vision Science have reinforced analyst optimism, with H.C. Wainwright and Stifel maintaining Buy ratings.

RA Capital Management, L.P., a director and 10% owner of SpyGlass Pharma, Inc. (NASDAQ:SGP), has expanded its position in the company with the purchase of 1,000 shares of common stock. The transaction, executed on November 16, 2026, was made at a weighted average price of $32.43 per share, with individual purchase prices ranging from $32.42 to $32.60. The total value of the acquisition amounted to $32,430.

The buy comes at a time when SpyGlass shares have experienced notable volatility. Since the purchase, the stock has declined to $29.68, marking an 11% drop over the past week. Despite this recent pullback, SpyGlass shares have surged 40% over the past six months, and the company currently carries a market capitalization of $993 million.

Following these transactions, RA Capital Management, L.P. indirectly holds 5,967,439 shares through RA Capital Healthcare Fund, L.P., and an additional 2,054,678 shares through RA Capital Nexus III Fund, L.P. RA Capital Management, L.P. serves as the investment manager for both funds. Dr. Zachary Scheiner, a principal of RA Capital Management, L.P., sits on SpyGlass Pharma's board of directors. RA Capital Management, L.P., its general partner RA Capital Management GP, LLC, and its managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah, disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest.

According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, though analysts maintain a strong buy consensus with price targets ranging from $42 to $62.

In other recent news, SpyGlass Pharma has reported several developments that have drawn investor attention. The company announced positive results from a four-year trial of its Bimatoprost Drug Pad-IOL System, demonstrating a 37% reduction in intraocular pressure among patients with mild-to-moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery. The promising trial data led H.C. Wainwright to reiterate its Buy rating and maintain a $37.00 price target for SpyGlass Pharma.

Additionally, SpyGlass Pharma recently acquired Advanced Vision Science, a manufacturer of intraocular lenses, for approximately $13 million in cash. This acquisition prompted Stifel to uphold its Buy rating with a $42.00 price target, emphasizing the strategic importance of the deal. Stifel also adjusted its price target on SpyGlass Pharma shares to $44.00 following a discussion with the company's management at the 2026 Stifel Healthcare Conference. These recent developments highlight the company's ongoing efforts to expand its product offerings and strengthen its market position.

Risks

  • The stock's 11% weekly decline and InvestingPro's overvaluation assessment suggest potential for further price correction, impacting near-term investor returns.
  • Insider purchases may not reliably predict future performance, and the disclosed transactions are relatively small in dollar terms, limiting their signal value.
  • Integration risks and regulatory hurdles associated with the Advanced Vision Science acquisition could affect SpyGlass's operational execution and financial results.

More from Insider Trading

Universal Electronics Director Eric Singer Offloads $1.15 Million in Stock Across Three Sessions Nov 19, 2026 Universal Electronics Director Offloads $703,700 in Shares as Stock Surges Nov 19, 2026 FRP Holdings Director John D. Baker II Increases Stake with $96,349 Purchase Nov 19, 2026 Astera Labs Accounting Chief Offloads $7,230 in Stock to Cover Taxes Nov 19, 2026 Rhythm Pharmaceuticals Director Offloads $1.1 Million in Stock Nov 19, 2026